Summit Therapeutics Inc. (SMMT) stock
SMMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$16.03−0.17 (-1.05%)
Close on Oct 30, 2026Market cap $12.79BP/E –Yield –
Earnings
Summit Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Oct 19, 2026
Q3 FY2026 · estimated, before the open
Revenue, Q2 FY2026
–
Non-GAAP net loss per basic and diluted share, Q2 FY2026
-$0.19
-$0.12 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Summit Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q3 FY2026ended Sep 30, 2026 | Oct 19, 2026Expected | – | – | – | – | – |
| Q2 FY2026ended Jun 30, 2026 | Jul 23, 2026after the close | – | – | -$0.28 | -$0.19 | Release |
| Q1 FY2026ended Mar 31, 2026 | Apr 30, 2026after the close | – | – | -$0.24 | -$0.15 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 23, 2026after the close | – | – | -$0.29 | -$0.14 | Release |
| Q3 FY2025ended Sep 30, 2025 | Oct 20, 2025before the open | – | – | -$0.31 | -$0.13 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 11, 2025after the close | – | – | -$0.76 | -$0.12 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 1, 2025after the close | – | – | -$0.09 | -$0.07 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 24, 2025before the open | – | – | -$0.08 | -$0.07 | Release |
| Q3 FY2024ended Sep 30, 2024 | Oct 30, 2024before the open | – | – | -$0.08 | -$0.05 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 6, 2024before the open | – | – | -$0.09 | -$0.05 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 1, 2024before the open | – | – | -$0.06 | -$0.05 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 20, 2024before the open | – | – | -$0.05 | -$0.04 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 7, 2023before the open | – | – | -$0.03 | – | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 9, 2023before the open | – | – | -$0.02 | – | Release |
| Q1 FY2023ended Mar 31, 2023 | May 11, 2023after the close | – | – | -$1.43 | – | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 9, 2023after the close | – | – | -$0.07 | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 9, 2022after the close | $220.00K | -83.2% | -$0.14 | – | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 11, 2022after the close | $235.00K | – | -$0.17 | – | Release |
| Q1 FY2022ended Mar 31, 2022 | May 11, 2022after the close | $250.00K | – | -$0.22 | – | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 17, 2022after the close | $251.00K | – | -$0.28 | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 15, 2021before the open | $1.31M | – | -$0.20 | – | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 11, 2021before the open | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 17, 2021after the close | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Summit Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Summit Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Summit Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- News
- News
- News
- News
- Results
- Results
- News
- News
- News
- News
- Results
- Results
- Results